Saturday 17 October 2026 Export XRTX’s income statement to Excel — free account

XORTX Therapeutics Inc.

In the quarter to June 2026, EPS fell 10.5% and free cash flow fell 318.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.24 0.18 −12.68%

Follow XRTX

Alert me

Market cap: $2.6M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.58

Revenue —

Net Income (3.74)

Free Cash Flow (5.28)

Net Debt (0.99)

Current Ratio 3.59

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.36

Past 5Y EPS Growth —

This Y EPS Growth 39.98%

Next Y EPS Growth 49.29%

Next Y revenue growth —

Next 5Y EPS Growth 7.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	2	1	1
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	4	3	1	2

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	1	1	0	0
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	17.32%	(33.21%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(3)	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	(1)	(1)	(1)	(4)
’23	(2)	(2)	(1)	(1)	(7)
’22	(3)	(2)	(1)	(4)	(9)
’21	(1)	(2)	0	(3)	(5)
’20	—	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(3)	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	(1)	(1)	(1)	(4)
’23	(3)	(2)	(1)	(1)	(7)
’22	(3)	(2)	(1)	(4)	(9)
’21	(1)	(2)	0	(3)	(5)
’20	—	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.58)	(1.05)	—	—	—
’25	(0.95)	(0.95)	(0.65)	(0.45)	(2.80)
’24	(6.20)	0.30	(1.00)	0.20	(5.75)
’23	(4.95)	(4.05)	(3.35)	6.90	(5.45)
’22	(9.45)	(4.05)	(4.05)	(6.75)	(24.75)
’21	(0.21)	(0.85)	(31.95)	0.55	(6.30)
’20	—	(0.04)	(0.04)	(0.20)	(6.48)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	48.50	57.95	37.77	43.27	268.52	9.90	5.30	2.55	Analyst estimates 2026–2028 Powerpack
	High	—	—	75.65	101.28	158.46	2,478.60	1,004.40	502.20	35.00	8.95
People
People	Employees	—	—	—	—	1	2	3	17	17	15
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(3)	0	(1)	(1)	(8)	(2)	(3)	(3)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(3)	0	(1)	(1)	(8)	(2)	(3)	(3)
	Depreciation	—	—	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(4.74)	(0.82)	(6.48)	(6.30)	(24.75)	(5.45)	(5.75)	(2.80)
	Cash flow	—	—	(1.16)	(0.23)	(3.67)	(22.11)	(30.28)	(16.61)	(6.39)	(2.92)
	Capex	—	—	0.00	0.00	(0.07)	(0.15)	(0.15)	(0.12)	(0.07)	(0.06)
	Free cash flow	—	—	(1.16)	(0.23)	(3.74)	(22.25)	(30.44)	(16.72)	(6.46)	(2.98)
	Book value	—	—	0.40	(0.27)	6.33	61.04	23.64	11.71	5.79	2.20
	Shares, m	—	—	1	1	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(1)	0	(1)	(5)	(9)	(7)	(4)	(3)
	Capex	—	—	0	0	0	0	0	0	0	0
	Free cash flow	—	—	(1)	0	(1)	(5)	(9)	(7)	(4)	(3)
Balance, $m
Balance, $m	Working capital	—	—	0	0	1	16	9	3	2	1
	Total debt	—	—	0	0	—	—	0	—	—	—
	Net debt	—	—	(1)	(1)	0	(15)	(10)	(3)	(2)	(1)
	Shareholders’ equity	—	—	0	0	1	13	7	5	3	2
Returns, %
Returns, %	ROA	—	—	(596.89)	(54.81)	(75.31)	(13.67)	(51.53)	(24.19)	(69.30)	(78.38)
	ROIC	—	—	0.00	0.00	(80.42)	0.00	0.00	(316.40)	(298.29)	(166.80)
	ROE	—	—	(7,549.59)	(1,316.93)	(247.50)	(18.45)	(75.86)	(37.08)	(83.06)	(98.00)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AFMDQ Affimed N.V.	$2.8M	— (loss-making)	— (loss-making)	−92.02% (below 0%: shrinking)	n/m	+46.95% (above 0%: growing)	100.00%	(9,216.90%)	Compare
HCWB HCW Biologics Inc.	$2.8M	— (loss-making)	— (loss-making)	+1,954.55% (above 0%: growing)	n/m	−20.84% (below 0%: shrinking)	(69.25%)	(2,335.03%)	Compare
SLXN Silexion Therapeutics Corp	$2.7M	— (loss-making)	—	—	n/m	−16.63% (below 0%: shrinking)	—	0.00%	Compare
GOVX GeoVax Labs Inc.	$2.6M	— (loss-making)	— (loss-making)	+183.44% (above 0%: growing)	n/m	+15.81% (above 0%: growing)	100.00%	0.00%	Compare
XRTX XORTX Therapeutics Inc.	$2.6M	— (loss-making)	—	—	n/m	−318.40% (below 0%: shrinking)	0.00%	0.00%
EIGRQ Eiger BioPharmaceuticals, Inc.	$2.6M	— (loss-making)	— (loss-making)	+41.06% (above 0%: growing)	n/m	+37.90% (above 0%: growing)	97.34%	(331.69%)	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
ELAB PMGC Holdings Inc.	$2.5M	— (loss-making)	—	+147.70% (above 0%: growing)	n/m	−44.95% (below 0%: shrinking)	29.52%	(292.91%)	Compare
NTBLQ Notable Labs, Ltd.	$2.4M	— (loss-making)	— (loss-making)	−96.88% (below 0%: shrinking)	n/m	−26.63% (below 0%: shrinking)	100.00%	(269,000.00%)	Compare
Median of peers	$2.6M	—	—	+147.70%	—	−0.41%	100.00%	(1,333.36%)

All 614 Biotechnology stocks →